Pubblicazioni

Biofluid Markers and Tissue Biopsies Analyses for the Prodromal and Earliest Phase of Parkinson's Disease  (2024)

Autori:
Pilotto, Andrea; Zanusso, Gianluigi; Antelmi, Elena; Okuzumi, Ayami; Zatti, Cinzia; Lupini, Alessandro; Bongianni, Matilde; Padovani, Alessandro; Hattori, Nobutaka
Titolo:
Biofluid Markers and Tissue Biopsies Analyses for the Prodromal and Earliest Phase of Parkinson's Disease
Anno:
2024
Tipologia prodotto:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Lingua:
Inglese
Formato:
A Stampa
Referee:
Nome rivista:
JOURNAL OF PARKINSON'S DISEASE
ISSN Rivista:
1877-7171
N° Volume:
14
Numero o Fascicolo:
s2
Intervallo pagine:
333-344
Parole chiave:
DOPA decarboxylase; cerebrospinal fluid; plasma biomarkers; prodromal Parkinson’s disease; seed amplification assays; α-synuclein
Breve descrizione dei contenuti:
The recent development of new methods to detect misfolded α-synuclein (αSyn) aggregates in biofluids and tissue biopsies in the earliest Parkinson's disease (PD) phases is dramatically challenging the biological definition of PD. The αSyn seed amplification methods in cerebrospinal fluid (CSF) showed high sensitivity and specificity for early diagnosis of PD and Lewy bodies disorders. Several studies in isolated REM sleep behavior disorders and other at-risk populations also demonstrated a high prevalence of CSF αSyn positivity and its potential value in predicting the phenoconversion to clinically manifested diseases. Growing evidence exists for αSyn aggregates in olfactory mucosa, skin, and other tissues in subjects with PD or at-risk subjects. DOPA decarboxylase and numerous other candidates have been additionally proposed for either diagnostic or prognostic purposes in earliest PD phases. The newly described αSyn detection in blood, through its quantification in neuronally-derived exosome vesicles, represents a technical challenge that could open a new scenario for the biological diagnosis of PD. Despite this growing evidence in the field, most of method of αSyn detection and markers still need to be validated in ongoing longitudinal studies through an accurate assessment of different prodromal disease subtypes and scenarios before being definitively implemented in clinical settings.
Pagina Web:
https://dx.doi.org/10.3233/JPD-240007
Id prodotto:
141766
Handle IRIS:
11562/1142866
ultima modifica:
28 novembre 2024
Citazione bibliografica:
Pilotto, Andrea; Zanusso, Gianluigi; Antelmi, Elena; Okuzumi, Ayami; Zatti, Cinzia; Lupini, Alessandro; Bongianni, Matilde; Padovani, Alessandro; Hattori, Nobutaka, Biofluid Markers and Tissue Biopsies Analyses for the Prodromal and Earliest Phase of Parkinson's Disease «JOURNAL OF PARKINSON'S DISEASE» , vol. 14 , n. s22024pp. 333-344

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

<<indietro
Condividi